Showing posts with label doctor prescription. Show all posts
Showing posts with label doctor prescription. Show all posts
Monday, October 5, 2026
Could psilocybin treat brain injuries? Neuroscientist explains how psychedelics could fill a gap in head trauma care
Sunday, September 27, 2026
Early statin therapy may lower risk for dementia in people with diabetes
Your competent? doctor immediately prescribed statins post stroke based on earlier research, right? NO? And still hasn't been fired yet?
1. Statins.
tested in rats from 2003
http://Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke
Simvastatin Attenuates Stroke-induced Splenic Atrophy and Lung Susceptibility to Spontaneous Bacterial Infection in Mice
Or,
Simvastatin attenuates axonal injury after experimental traumatic brain injury and promotes neurite outgrowth of primary cortical neurons
October 2012
tested in humans, March 2011
http://www.medwirenews.com/39/91658/Stroke/Acute_statin_therapy_improves_survival_after_ischemic_stroke.html
And now lost even to the Wayback Machine
So, I think this below is the actual research.
Association Between Acute Statin Therapy, Survival, and Improved Functional Outcome After Ischemic Stroke April 2011
The latest here:
Early statin therapy may lower risk for dementia in people with diabetes
Key takeaways:
- Statin initiation after diagnosis of diabetes may lower risk for developing dementia vs. no statin initiation.
- Treating CV risk factors may also prevent cognitive decline in people with diabetes.
MUNICH — Statin initiation after a diagnosis of type 2 diabetes was associated with lower absolute and relative risk for all-cause dementia compared with no statin initiation, a speaker reported.
The effect was most pronounced in patients who initiated statin therapy within 1 year of their type 2 diabetes diagnosis, according to the researchers.
Addressing traditional CV risk factors could also prevent development of dementia among people with diabetes, according to data presented at the European Society of Cardiology Congress and simultaneously published in The Lancet Regional Health – Europe.
“As we become better at treating some of the main killers, like heart disease, cancers and infectious diseases, we are seeing a progressively aging population, globally. We all see a large burden of dementia, especially in diabetes. As we don’t have any cure for dementia, attention has turned toward preventing it by targeting some of the cardiovascular risk factors that we see. Diabetes and elevated low-density lipoprotein cholesterol have been highlighted as two such risk factors,” Tummas Ternhamar, MD, clinical researcher at Copenhagen University Hospital and University of Copenhagen, Denmark, said during a presentation. “What we wanted to test was the hypothesis that early statin treatment at the point when a type 2 diabetes diagnosis is made is associated with lower risk of dementia [compared with] delayed initiation.”
Ternhamar and colleagues used nationwide registry data gathered from 2006 to 2019 to identify 132,585 individuals with a diagnosis of type 2 diabetes who were statin-naive. Participants were sorted into one of three categories: no statin initiation within 5 years after diabetes diagnosis; early statin initiation within 1 year of diagnosis; and late statin initiation at 1 to 5 years after diabetes diagnosis.
Participants were followed for a median of 7.1 years, and the primary outcome was 10-year risk for all-cause dementia, with death treated as a competing risk.
The researchers estimated that the 10-year absolute risk for dementia was 3.9% among patients who did not initiate a statin after diabetes diagnosis; 3.3% among those who initiated early; and 3.5% among those who initiated late after diabetes diagnosis.
Compared with no statin initiation, early statin treatment was associated with a 15% lower 10-year relative risk for dementia (95% CI, 9%-21%) and late statin initiation was associated with a 10% lower 10-year relative risk for dementia (95% CI, 3%-15%), according to the study.
The researchers estimated that early statin initiation after diabetes diagnosis was associated with an absolute risk difference of 0.59% (95% CI, 0.34%-0.86%) while late statin initiation was associated with a 0.38% absolute risk difference (95% CI, 0.12%-0.61%) compared with no statin initiation.
“In statin-naive individuals who developed diabetes, statin therapy was associated with a lower relative and absolute risk of dementia, which was most pronounced in those with early statin initiation,” Ternhamar said during the presentation. “It highlights potential for targeting some of the traditional cardiovascular risk factors, LDL cholesterol in this case, for improving brain health and dementia risk.”
Friday, September 11, 2026
Scientists fed people tomatoes—3 months later, their brains had changed
Somehow your incompetent? doctor missed prescribing this well over a decade ago! And you haven't gotten them fired yet? And removed the incompetent board of directors?
- lycopene
(27 posts to October 2012)
Scientists fed people tomatoes—3 months later, their brains had changed
The best tomatoes have the deepest red color. They’re juicier, sweeter and more flavorful, with high levels of lycopene, one of their biggest nutritional benefits.
But what exactly is lycopene, and why is it so important?
According to the International Food Information Council, “Lycopene provides the pigment that gives red and pink fruits their color and is known to have antioxidant properties.
More Powerful
“It’s most commonly associated with tomatoes and tomato products, which are particularly rich sources of lycopene.”
The antioxidant has long been linked to significant health benefits, but a new study published in Antioxidants suggests its effects may be even more powerful than previously believed.
WebMD notes that lycopene has previously been believed to improve heart health, reduce cancer risk, improve skin health, provide pain relief and improve fertility in men.
Now, research is suggesting that the antioxidant plays an important role in brain function—particularly in middle-aged adults.
The study enlisted 47 adults ranging in age from 40 to 55 years old. Participants were assigned to two three-month interventions separated by a one-month washout.
Each day, they were to consume 0.5 grams of tomato paste for every kilogram of body weight, while also consuming a control lycopene-restricted diet.
‘Changes in brain network’
Prior to beginning the study, participants’ cognitive performance was evaluated using validated neuropsychological tests alongside plasma lycopene and brain-derived neurotrophic factor (BDNF), as well as resting-state functional magnetic resonance imaging (fMRI).
At the end of the trial, study authors determined that tomato intake improved selective attention and associative memory.
“Resting-state fMRI revealed changes in brain networks, including reduced connectivity in frontoparietal and auditory networks, contrasting with reductions in the dorsal attention network during the control period,” study authors added.
These findings indicate exciting results that tomato intake could be directly linked to improved cognitive function and modulate brain connectivity in healthy middle-aged adults.
Positive Signs
“To our knowledge, this is the first clinical trial to link changes in the antioxidant lycopene with alterations in functional brain connectivity,” the study authors noted.
“Specifically, increased lycopene correlated with reduced connectivity in the right frontoparietal network and enhanced connectivity in the dorsal attention network, the latter consistent with prior observational evidence that lycopene modulates this network.”
While this study is just the beginning, it takes positive steps towards the use of high-lycopene fruits to improve brain function.
So, if you are looking to better your memory or feel sharper each day, perhaps it is a good idea to keep tomatoes in mind—pun intended.
Newsweek has reached out to study authors for comment via email.
Related Articles
Thursday, August 20, 2026
Cocoa Polyphenols May Benefit Mood and Brain Health, Research Suggests
Didn't your competent? doctor prescribe cocoa years ago, even with limited proof? NO? So, COMPLETELY FUCKING INCOMPETENT!
- cocoa
(29 posts to August 2012) Make sure to get all the way to the 2012 one.
- Cocoa flavanols
(14 posts to April 2015)
Cocoa Polyphenols May Benefit Mood and Brain Health, Research Suggests
Wednesday, August 19, 2026
Inhaled cannabis reduces number of daily ectopic heart beats
Since I'm sure your doctor never prescribed marijuana post stroke you'll never hear of this.
My 13 reasons for marijuana use post-stroke. June 2014
Don't follow me, I'm not medically trained, and I don't have a Dr. in front of my name.
An ectopic heartbeat is an extra or early heartbeat that interrupts your normal heart rhythm. It can make your heart feel like it skipped a beat, paused, or gave a strong thump. Most extra beats are harmless, very common, and do not mean you have a serious heart disease.
Inhaled cannabis reduces number of daily ectopic heart beats
Key takeaways:
- Lower rates of ectopic heart beats on days in which habitual users inhaled cannabis vs. days of nonuse.
- Cannabis use in this cohort had no impact on daily steps, sleep duration or blood glucose.
Inhaled cannabis use was associated with acute reductions in ectopic heart beats vs. nonuse, mainly driven by reductions in premature atrial contractions, researchers reported.
The present study among habitual cannabis users identified certain acute effects of the drug on cardiac function, but no impact on daily steps count, sleep duration and glucose changes on days of use vs. nonuse was observed, according to data published in the Journal of the American College of Cardiology.
“Recreational cannabis is now legal in more than half the U.S. and is becoming more commonly used, but we know very little about the true health effects of the drug. At the same time, there is a growing interest in identifying modifiable risk factors that may influence risks of common heart rhythm disturbances. Prior work related to cannabis and arrhythmias has generally suggested harm, but has been conflicting,” Gregory M. Marcus, MD, MAS, cardiologist and Endowed Professor of Atrial Fibrillation Research in the division of cardiology at the University of California, San Francisco, told Healio.
The MARY-JANE trial was a prospective, randomized study conducted at the University of California, San Francisco. Researchers enrolled 108 habitual cannabis users who reported inhaled cannabis use at least once in the past month and 4 or more days within a week at least once in the past year. Participants had to be willing to abstain from cannabis use for at least 2 consecutive days over the 14-day trial period, according to the study methods.
Participants received a continuously recording ECG patch (Zio XT Patch, iRhythm), a Bluetooth-enabled, wrist-worn accelerometer and sleep monitoring device (Fitbit INSPIRE devices, Fitbit) and a Bluetooth-enabled continuous glucose monitor device (Dexcom G7, Dexcom).
Participants were randomly assigned via daily text message to either use or abstain from inhaled cannabis.
The primary outcome was daily cardiac ectopy, defined as total daily premature atrial and ventricular contractions. Mean daily steps, sleep duration per night and daily glucose changes were also evaluated, according to the study methods.
The researchers reported that although the mean age of study participants was 32 years, individuals representing each decade of life from age 21 into their 70s participated (59% women; 37% white).
Adherence to daily randomization was reported to be a challenge in the present study. However, the researchers wrote “it should not explain false positive results with regard to our prespecified primary endpoint or assessments of autonomic tone”
Inhaled cannabis was associated with a 9% reduction in ectopic beats (rate ratio [RR] = 0.91; 95% CI, 0.85-0.98; P = .02); a 10% reduction in daily premature atrial contractions (RR = 0.9; 95% CI, 0.82-0.97; P = .012); and no change in premature ventricular contractions (P = .83) compared with nonuse, according to the study.
Researchers reported that each inhalation of cannabis was associated with an approximately 2% reduction in ectopic beats (RR = 0.98; 95% CI, 0.97-0.99; P = .043).
“Contrary to our hypothesis, we failed to show that random assignment to use inhaled cannabis increased common cardiac ectopy. Of note, increasing frequencies of premature atrial contractions are an important predictor of atrial fibrillation, and those with more premature ventricular contraction frequencies have a higher risk for heart failure. In fact, we found a small decrease in cardiac ectopy, driven mainly by less premature atrial contractions, on days when participants were randomly assigned to smoke or vape cannabis,” Marcus told Healio. “At the same time and after excluding those ectopic beats from the continuous ECG data, we did see evidence of increased punctuated sympathetic activity on days randomized to cannabis, consistent with an increase in THC exposure on those days. Other methods to assess compliance suggested that participants generally followed their randomization assignment most of the time.”
Mean daily steps, sleep duration per night and daily glucose changes were not significantly different between inhaled cannabis use and nonuse, according to the study.
“This single study should not be considered sufficient to change clinical practice or recommendations, but should justify opening up future investigations and lines of inquiry as to how cannabis might actually have antiarrhythmic properties. It also challenges the notion that all inhaled smoke is the same, particularly given quite clear evidence that inhaled tobacco smoke has been consistently associated with more cardiac ectopy,” Marcus told Healio.
For more information:
Gregory M. Marcus, MD, MAS, can be reached at greg.marcus@ucsf.edu or X @gregorymmarcus.
Cocoa flavanols protect endothelial function during prolonged sitting in healthy older adults
Since you are massively sedentary during your hospital stay will your doctor at least prescribe cocoa? Oh NO, you DON'T have a functioning stroke doctor, do you? Doesn't read or implement research; just a flaccid walking/talking doctor impersonator! But first needs to initiate research in stroke subjects!
Cocoa flavanols protect endothelial function during prolonged sitting in healthy older adults
Catarina Rendeiro
Sitting time is high in older adults and has been shown to temporarily impair endothelial function and blood pressure (BP). Flavanols, plant-derived compounds, acutely enhance endothelial function and reduce BP in older adults. The aim of this study was to investigate whether acute ingestion of cocoa flavanols can improve peripheral endothelial function and BP during prolonged sitting in healthy older adults. In a randomised, double-blinded, within-subject, cross-over, placebo-controlled human study, 20 apparently healthy, older adults (age, 72.4 ± 5.0 years; 7 males, 13 females) consumed a high-flavanol (695 mg) and a low-flavanol (5.6 mg) cocoa beverage immediately before a 2-hour sitting bout. Flow-mediated dilation (FMD) of the superficial femoral (SFA; primary outcome) and brachial (BA) arteries, and BP, were assessed before and after sitting. Microvasculature haemodynamics were assessed in the gastrocnemius before, during, and after sitting. Sitting reduced both SFA FMD (Δ = −0.7%; p = 0.005) and BA FMD (Δ = −0.7%; p = 0.016) in the low-flavanol condition. The high-flavanol intervention prevented the decline in both SFA and BA FMD following sitting, with FMD measures remaining similar to pre-sitting (p > 0.3). Sitting increased both systolic (Δ = 6.1 mm Hg, p = 0.001) and diastolic BP (Δ = 2.6 mm Hg, p = 0.001), with no benefit from flavanol intake. Sitting increased muscle oxygenation resting levels (p < 0.001) and haemoglobin content (p < 0.001), and decreased muscle oxygen consumption during SFA occlusion (p < 0.001). Flavanols had no effect on the muscle microvasculature. These findings indicate that flavanol-rich foods may be efficacious nutritional strategies to counteract sitting-induced endothelial impairments during prolonged sitting in older adults, but do not alleviate sitting-induced increases in BP.
Visual Abstract
Two hours of sitting impaired upper and lower limb endothelial function (flow-mediated dilation; FMD) and increased blood pressure in healthy older adults. Consuming flavanols prior to sitting preserved endothelial function in both conduit arteries.
Friday, May 8, 2026
Erectile Dysfunction Drugs Linked to Lower Glaucoma Risk in Men
Didn't your competent? doctor already prescribe this for stroke recovery and dementia risk reduction?
- Sildenafil
(6 posts to November 2012)
- 16 posts on Viagra here.
Erectile Dysfunction Drugs Linked to Lower Glaucoma Risk in Men
Also from ARVO: HDL and AMD risk in women, statin use and glaucoma risk
DENVER -- Men using phosphodiesterase type 5 (PDE-5) inhibitors for erectile dysfunction (ED) had a modestly lower risk of glaucoma, according to a study reported here.
During 3 years of follow-up, men taking PDE-5 inhibitors had a reduced likelihood for glaucoma suspect (risk factors) and open-angle glaucoma (OAG). The absolute difference ranged from 1-3% for glaucoma suspect and about 1% for OAG. The relative risk differential achieved statistical significance each year for both conditions (P=0.04 to P<0.01).
"The association is likely vascular in origin, as PDE-5 inhibitors enhance [nitric oxide-cyclic guanosine monophosphate] signaling, improving ocular blood flow and optic nerve perfusion," concluded Abdelrahman M. Elhusseiny, MD, of the University of Miami, and colleagues in a poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) meeting. "PDE-5 inhibitors do not produce sustained intraocular pressure reduction, suggesting the effect is not mediated by aqueous humor dynamics. Further prospective studies are needed to clarify mechanisms, evaluate long-term effects, and determine clinical implications."
PDE-5 inhibitors (such as sildenafil [Viagra], tadalafil [Cialis], and vardenafil [Levitra]) are prescribed primarily for ED and pulmonary hypertension, but the drugs' vascular and cryoprotective effects may have broader therapeutic implications, the investigators noted. To examine the issue, they queried the TriNetX clinical network for the years 2005-2025 to identify men at least 40 years old with diagnosed ED, and then grouped them according to history of PDE-5 inhibitor use.
The primary analysis included two propensity-matched groups of 23,603 men each (PDE-5 users and non-users). Mean follow-up in each group was almost 1,000 days. The primary endpoints were glaucoma suspect and OAG.
After a year of follow-up, rates of glaucoma suspect and OAG were 6.49% and 2.13% versus 9.73% and 3.22% for PDE-5 inhibitor users and non-users, respectively (P<0.01 for both comparisons). Rates of both conditions increased in both groups and between-group differences shrank during the next 2 years. At the end of follow-up, rates of glaucoma suspect and OAG were 11.17% and 3.88% among PDE-5 inhibitor users versus 12.06% (P=0.01) and 4.28% (P=0.04) among non-users.
Higher HDL Linked to Lower AMD Risk in Women
Higher levels of high-density lipoprotein (HDL) in women were associated with a small but statistically significant lower risk of developing neovascular age-related macular degeneration (nAMD), according to a study reported at ARVO.
Women with HDL levels ≥60 mg/dL had a 1% absolute difference in nAMD (10.2% vs 11.2%) with women who had low HDL (<50 mg/dL). The difference translated into a 9% reduction in relative risk (95% CI 0.83-0.99, P=0.03). However, the difference no longer remained significant in a time-to-event analysis (HR 0.93, 95% CI 0.85-1.02, P=0.11). A comparison of low versus normal HDL (50-59 mg/dL) showed no difference, and neither high nor low HDL levels altered nAMD risk in men.
"These findings suggest there may be sex-specific, lipid-related mechanisms involved in AMD progression, and highlight the need for further research into the role of HDL and retinal disease biology," said Adriana Kaganovski, of SUNY Downstate Health Sciences University in New York City, in a recorded summary of the study.
Lipid metabolism has been implicated in AMD pathogenesis but the influence of HDL on AMD risk remains unclear, said Kaganovski. To examine whether sex-specific HDL categories are associated with AMD risk, investigators searched the TriNetX network to identify adults with diagnosed nAMD and HDL measurements within 6 months of diagnosis. Men and women were stratified by sex-specific HDL levels for comparisons of high versus low and low versus normal levels.
Data analysis involved matched cohorts (4,347 to 8,911 participants each) to compare nAMD prevalence by HDL levels in men and women. For men, nAMD prevalence was 9-10% regardless of HDL level. Among women, nAMD prevalence was about 10-11%, and only the comparison of high versus low HDL produced a statistically significant difference.
Statin Use and Glaucoma Risk
Previously documented neuroprotective effects of statins may extend to glaucoma, according to a retrospective analysis involving more than 500,000 patients.
Statin use was modestly associated with the 5-year incidence of OAG (5.0% vs 5.3%, P<0.001). In a separate analysis of glaucoma-associated surgery, reflecting progressive disease, statin users had significantly lower hazards for incisional surgery, minimally invasive glaucoma surgery (MIGS), and selective laser trabeculoplasty (SLT).
"Our results are consistent with our hypothesis that statin use is associated with lower risk of glaucoma onset and progression," concluded Forest Lin, of the University of South Florida in Tampa, and colleagues in a poster presentation. "Prospective trials are needed to further elucidate the relationship between statin usage and glaucoma."
Statins' neuroprotective potential in glaucoma remains poorly understood, as previous studies have yielded inconsistent results, the investigators noted. To inform the issue, they tested the hypothesis that statin use would be associated with a decreased risk of OAG and progressive disease, as reflected in surgery and other interventions.
A search of the TriNetX database produced matched cohorts of 218,677 patients each for the analysis of glaucoma incidence and matched cohorts of 51,551 patients each for the analysis of progressive disease.
Over a 5-year period, 10,223 statin users and 10,801 non-users had new diagnoses of OAG, a difference that translated into a 9% reduction in the hazard ratio (95% CI 0.89-0.94). Statin use was associated with larger reductions in HRs for incisional surgery (HR 0.83, 95% CI 0.78-0.88), MIGS (HR 0.82, 95% CI 0.78-0.87), and SLT (HR 0.88, 95% CI 0.84-0.92). Statin users were more likely to be treated with ocular hypotensive agents (HR 1.39, 95% CI 1.37-1.41).
Wednesday, March 11, 2026
Regular Multivitamin Use Associated With Slower Aging in Older Adults: Study
You competent? doctor has already prescribed multivitamins based on all this earlier resesarch, right! Oh NO; NO KNOWLEDGE AND NO PRESCRIPTION!
- multivitamin
(11 posts to May 2015)
Call the president and ask about hiring competent persons!
Regular Multivitamin Use Associated With Slower Aging in Older Adults: Study
Sunday, March 1, 2026
NMN improves high-fat-diet-induced myocardial damage of aging mice through Sirt3/PINK1/Parkin signaling pathway
Didn't your competent? doctor prescribe NMN years ago? NO? So fucking incompetence reigned and your doctor is still employed?
Editorial: Inflammation in ischemic stroke and novel therapeutic strategies for stroke treatment November 2022
The latest here:
NMN improves high-fat-diet-induced myocardial damage of aging mice through Sirt3/PINK1/Parkin signaling pathway
Subscribe to:
Posts (Atom)